Literature DB >> 1686406

Treatment of benzodiazepine withdrawal symptoms with carbamazepine.

D Garcia-Borreguero1, T Bronisch, S Apelt, A Yassouridis, H M Emrich.   

Abstract

In 18 patients with a benzodiazepine (BZD) dependency the drug was withdrawn. The dose of BZD was gradually reduced in nine of the patients, while the others were additionally treated with carbamazepine (CBZ) for a further 15 days after BZD discontinuation. Withdrawal symptoms were assessed every third day during the study period. When comparing results in both groups, a clear trend towards less severe withdrawal symptoms could be observed in the group treated with CBZ. Some of the differences were statistically significant on days 9-12 after BZD withdrawal. Fundamental withdrawal symptoms (like hypersensitivity to sensory stimuli, abnormal perception of movement, depersonalisation or derealisation) were also less severe in the group treated with CBZ compared with the group not receiving that treatment. These findings support the results of previous reports indicating a therapeutical effect of CBZ in BZD withdrawal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686406     DOI: 10.1007/bf02219713

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  38 in total

1.  Sodium valproate in benzodiazepine withdrawal.

Authors:  S Apelt; H M Emrich
Journal:  Am J Psychiatry       Date:  1990-07       Impact factor: 18.112

2.  Withdrawal reaction after long-term therapeutic use of benzodiazepines.

Authors:  U Busto; E M Sellers; C A Naranjo; H Cappell; M Sanchez-Craig; K Sykora
Journal:  N Engl J Med       Date:  1986-10-02       Impact factor: 91.245

3.  Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients.

Authors:  K Rickels; W G Case; E E Schweizer; C Swenson; R B Fridman
Journal:  Psychopharmacol Bull       Date:  1986

Review 4.  Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses.

Authors:  J C Ballenger; R M Post
Journal:  Psychopharmacol Bull       Date:  1984

5.  Effect of carbamazepine on cyclic nucleotides in CSF of patients with affective illness.

Authors:  R M Post; J C Ballenger; T W Uhde; C Smith; D R Rubinow; W E Bunney
Journal:  Biol Psychiatry       Date:  1982-09       Impact factor: 13.382

6.  Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome.

Authors:  E Schweizer; K Rickels; W G Case; D J Greenblatt
Journal:  Arch Gen Psychiatry       Date:  1991-05

7.  Withdrawal from long-term benzodiazepine treatment.

Authors:  H Petursson; M H Lader
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-05

8.  Carbamazepine treatment for benzodiazepine withdrawal.

Authors:  R K Ries; P P Roy-Byrne; N G Ward; V Neppe; S Cullison
Journal:  Am J Psychiatry       Date:  1989-04       Impact factor: 18.112

9.  Schneiderian first-rank symptoms caused by benzodiazepine withdrawal.

Authors:  K Roberts; N Vass
Journal:  Br J Psychiatry       Date:  1986-05       Impact factor: 9.319

Review 10.  Benzodiazepine withdrawal: overview and implications for the treatment of anxiety.

Authors:  P P Roy-Byrne; D Hommer
Journal:  Am J Med       Date:  1988-06       Impact factor: 4.965

View more
  2 in total

1.  Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment.

Authors:  Øistein Kristensen; Terje Lølandsmo; Ase Isaksen; John-Kåre Vederhus; Thomas Clausen
Journal:  BMC Psychiatry       Date:  2006-11-15       Impact factor: 3.630

Review 2.  Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.

Authors:  Lone Baandrup; Bjørn H Ebdrup; Jesper Ø Rasmussen; Jane Lindschou; Christian Gluud; Birte Y Glenthøj
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.